InnoCan Pharma (INNO) Q4 2024 earnings summary

Executive summary

• Revenues more than doubled year-over-year to US $29.4 million for 2024, driven by strong sales from the BI Sky Global subsidiary.

• Gross profit rose 118.6% year-over-year to US $26.2 million, reflecting improved operational efficiency.

• Operating loss narrowed by 67% to US $1.2 million in 2024, compared to US $3.8 million in 2023.

• Management emphasized commitment to innovation, particularly in non-opioid chronic pain management and beauty/personal care markets.

Financial highlights

• Revenue increased 114.6% year-over-year to US $29.4 million, up from US $13.7 million in 2023.

• Gross profit reached US $26.2 million, up from US $12.0 million in the prior year.

• Operating loss reduced to US $1.2 million, a significant improvement from US $3.8 million in 2023.

Outlook and guidance

• Plans to advance both human and animal applications for the LPT-CBD platform, focusing on non-opioid chronic pain management.

• Intends to strengthen its position in the beauty and personal care industry through BI Sky Global.